ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug
April 28, 2025PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data. -
Patients Win When Support Is Personalized: New Study From Atlantis Healthcare Shows Treatment Persistence and Adherence Improved by 38%
March 08, 2021Leading patient outcomes journal Patient Preference and Adherence has published a study that demonstrates significant improvement in treatment behaviors among patients with neovascular age-related macular degeneration (nAMD) who received personalized ... -
EyePoint Announces First Patient Dosed in Trial of EYP-1901 for Wet AMD
February 03, 2021EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
Pharma Sources Insight January 2025
